Wockhardt LimitedNSE: WOCKPHARMA

Press Release Mar 30 2026

· Issued by Wockhardt Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Wockhardt Limited has submitted a press release regarding its antibiotic Zaynich® (Zidebactam/Cefepime) receiving a favorable recommendation from the CDSCO’s Subject Expert Committee for treating Gram-negative infections. This recommendation is a significant step towards obtaining final approval from the Drugs Controller General of India. The press release outlines the extensive clinical evaluation and efficacy of Zaynich® in treating resistant infections, highlighting its potential impact on public health.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release -"Wockhardt's Zaynich® (Zidebactam/Cefepime) Receives Favourable Recommendation from CDSCO's Subject Expert Committee for Treatment of Gram-Negative Infections".

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases